Pilot supports real-world endpoints as surrogates for OS

Friends of Cancer Research released data Tuesday that support the use of real-world evidence (RWE) outcomes -- including real-world progression-free survival (rwPFS) -- as surrogate endpoints for overall survival to evaluate a treatment's long-term effects.

In the pilot program, a working group led by the non-profit Friends evaluated electronic health records (EHR) and claims data from non-small cell lung cancer patients receiving anti-PD-L1 mAb Tecentriq atezolizumab and anti-PD-1 mAbs Opdivo nivolumab and Keytruda pembrolizumab in the postmarket setting. Friends measured the correlation between several real-world endpoints and OS using Spearman’s rank correlation co-efficient, which ranges from 1 when the variables are identical to -1 when they are fully opposed...